We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Tool for Lyme Disease Testing Boasts Over 90% Accuracy

By LabMedica International staff writers
Posted on 23 Sep 2024

Lyme disease is on the rise globally, with an estimated 14% of the population having been infected at some point. More...

Many of these individuals experience chronic symptoms due to delayed diagnosis. A recent study found that 38% of Lyme patients continue to suffer from symptoms six months after their initial diagnosis, highlighting the need for better testing methods. Until now, tests for Lyme disease have been less than 50% accurate, particularly in the early stages, leading to numerous cases of misdiagnosis or undiagnosed patients, resulting in prolonged suffering. Now, a new test with over 90% accuracy, capable of detecting the disease at all stages, including the crucial first 14 days post-infection, represents a potential breakthrough in Lyme disease diagnosis.

Developed through a collaboration between Tulane University (New Orleans, LA, USA) and Focus on Lyme (Phoenix, AZ, USA), the new diagnostic, LymeSeek, is enhanced by machine learning and has the potential to transform Lyme disease detection. The test's high accuracy is achieved through a combination of multiple biomarkers and a unique algorithm, providing over 90% accuracy in all phases of the disease. Unlike other tests that claim similar accuracy but rely solely on two-tier testing, LymeSeek's accuracy is based on samples from the early stages of the disease, including cases with erythema migrans (EM) rash, PCR, and/or punch biopsy results, which are often missed by current testing methods.

This patented test will enable timely and precise diagnosis of Lyme disease during its most treatable phase. The current diagnostic process for Lyme disease involves multiple steps, takes over a week, and requires subjective interpretation. LymeSeek aims to replace this lengthy procedure, facilitating earlier diagnoses and reducing the incidence of chronic illness caused by delayed or missed diagnoses. Ongoing efforts are focused on further development and manufacturing, with plans to pursue early FDA clearance, aiming to make LymeSeek available to the public by the third quarter of 2026.

Related Links:
Tulane University 
Focus on Lyme


New
Gold Member
Latex Test
SLE-Latex Test
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Myocardial Infarction Test
Quidel Triage Cardio3 Panel
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Results of AI-based 3D virtual H&E staining and quantitative analysis of pathological tissue (Photo courtesy of Nature Communications, DOI:10.1038/s41467-025-59820-0)

Virtual Staining Technology Paves Way for Non-Invasive Pathological Diagnosis

For more than 200 years, traditional pathology has depended on the technique of examining cancer tissues under a microscope, a method that provides only limited, specific cross-sections of the 3D structure... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.